Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 48

1.

Novel Protein Kinase Inhibitors Related to Tau Pathology Modulate Tau Protein-Self Interaction Using a Luciferase Complementation Assay.

Holzer M, Schade N, Opitz A, Hilbrich I, Stieler J, Vogel T, Neukel V, Oberstadt M, Totzke F, Schächtele C, Sippl W, Hilgeroth A.

Molecules. 2018 Sep 12;23(9). pii: E2335. doi: 10.3390/molecules23092335.

2.

Discovery of Novel Enhancers of Isoniazid Toxicity in Mycobacterium tuberculosis.

Lentz F, Reiling N, Martins A, Molnár J, Hilgeroth A.

Molecules. 2018 Apr 4;23(4). pii: E825. doi: 10.3390/molecules23040825.

3.

Novel Effective Small-Molecule Antibacterials against Enterococcus Strains.

Ashraf K, Yasrebi K, Hertlein T, Ohlsen K, Lalk M, Hilgeroth A.

Molecules. 2017 Dec 10;22(12). pii: E2193. doi: 10.3390/molecules22122193.

4.

Discovery of novel dual inhibitors of receptor tyrosine kinases EGFR and PDGFR-β related to anticancer drug resistance.

Fischer T, Najjar K, Totzke F, Schächtele C, Sippl W, Ritter C, Hilgeroth A.

J Enzyme Inhib Med Chem. 2018 Dec;33(1):1-8. doi: 10.1080/14756366.2017.1370583.

5.

Discovery of novel substituted benzo-anellated 4-benzylamino pyrrolopyrimidines as dual EGFR and VEGFR2 inhibitors.

Fischer T, Krüger T, Najjar A, Totzke F, Schächtele C, Sippl W, Ritter C, Hilgeroth A.

Bioorg Med Chem Lett. 2017 Jun 15;27(12):2708-2712. doi: 10.1016/j.bmcl.2017.04.053. Epub 2017 Apr 19.

PMID:
28478927
6.

Discovery of novel dual inhibitors of receptor tyrosine kinases EGFR and IGF-1R.

Hempel C, Totzke F, Schächtele C, Najjar A, Sippl W, Ritter C, Hilgeroth A.

J Enzyme Inhib Med Chem. 2017 Dec;32(1):271-276. doi: 10.1080/14756366.2016.1247062.

7.

Discovery of novel N-phenyl 1,4-dihydropyridines with a dual mode of antimycobacterial activity.

Lentz F, Hemmer M, Reiling N, Hilgeroth A.

Bioorg Med Chem Lett. 2016 Dec 15;26(24):5896-5898. doi: 10.1016/j.bmcl.2016.11.010. Epub 2016 Nov 11.

PMID:
27866817
8.

Novel inhibitors of the methicillin-resistant Staphylococcus aureus (MRSA)-pyruvate kinase.

El-Sayed MT, Zoraghi R, Reiner N, Suzen S, Ohlsen K, Lalk M, Altanlar N, Hilgeroth A.

J Enzyme Inhib Med Chem. 2016 Dec;31(6):1666-71. doi: 10.3109/14756366.2015.1118685. Epub 2015 Dec 10.

PMID:
26653005
9.

Discovery of bisindolyl-substituted cycloalkane-anellated indoles as novel class of antibacterial agents against S. aureus and MRSA.

El-Sayed MT, Suzen S, Altanlar N, Ohlsen K, Hilgeroth A.

Bioorg Med Chem Lett. 2016 Jan 1;26(1):218-21. doi: 10.1016/j.bmcl.2015.10.085. Epub 2015 Oct 29.

PMID:
26590101
10.

Novel 4-anilino-α-carboline derivatives induce cell death in nonadhesive breast cancer cells through inhibition of Brk activity.

Oelze M, Mahmoud KA, Sippl W, Wersig T, Hilgeroth A, Ritter CA.

Int J Clin Pharmacol Ther. 2015 Dec;53(12):1052-5. doi: 10.5414/CPXCES14EA07. No abstract available.

PMID:
26396134
11.

Discovery of substituted 1,4-dihydroquinolines as novel class of ABCB1 modulators.

Hemmer M, Krawczyk S, Simon I, Lage H, Hilgeroth A.

Bioorg Med Chem. 2015 Aug 1;23(15):5015-21. doi: 10.1016/j.bmc.2015.05.016. Epub 2015 May 15.

PMID:
26059595
12.

Discovery of substituted 1,4-dihydroquinolines as novel promising class of P-glycoprotein inhibitors: First structure-activity relationships and bioanalytical studies.

Hemmer M, Krawczyk S, Simon I, Hilgeroth A.

Bioorg Med Chem Lett. 2015 Aug 1;25(15):3005-8. doi: 10.1016/j.bmcl.2015.05.018. Epub 2015 May 22.

PMID:
26048803
13.

Synthesis, cytostatic evaluation and structure activity relationships of novel bis-indolylmethanes and their corresponding tetrahydroindolocarbazoles.

El Sayed MT, Ahmed KM, Mahmoud K, Hilgeroth A.

Eur J Med Chem. 2015 Jan 27;90:845-59. doi: 10.1016/j.ejmech.2014.12.008. Epub 2014 Dec 11.

PMID:
25528338
14.

Discovery of 9,10-Dihydroacridines as Novel Class of ABCB1 Inhibitors.

Hilgeroth A, Hemmer M, Neuber S, Molnár J, Lage H.

Med Chem. 2015;11(4):329-35.

PMID:
25391533
15.

Discovery of 4-anilino α-carbolines as novel Brk inhibitors.

Mahmoud KA, Krug M, Wersig T, Slynko I, Schächtele C, Totzke F, Sippl W, Hilgeroth A.

Bioorg Med Chem Lett. 2014 Apr 15;24(8):1948-51. doi: 10.1016/j.bmcl.2014.03.002. Epub 2014 Mar 12.

PMID:
24650640
16.

Recent developments of protein kinase inhibitors as potential AD therapeutics.

Tell V, Hilgeroth A.

Front Cell Neurosci. 2013 Nov 19;7:189. doi: 10.3389/fncel.2013.00189. Review.

18.

Development of small-molecule P-gp inhibitors of the N-benzyl 1,4-dihydropyridine type: novel aspects in SAR and bioanalytical evaluation of multidrug resistance (MDR) reversal properties.

Baumert C, Günthel M, Krawczyk S, Hemmer M, Wersig T, Langner A, Molnár J, Lage H, Hilgeroth A.

Bioorg Med Chem. 2013 Jan 1;21(1):166-77. doi: 10.1016/j.bmc.2012.10.041. Epub 2012 Nov 3.

PMID:
23199479
19.

Novel structurally varied N-alkyl 1,4-dihydropyridines as ABCB1 inhibitors: structure-activity relationships, biological activity and first bioanalytical evaluation.

Hilgeroth A, Baumert C, Coburger C, Seifert M, Krawczyk S, Hempel C, Neubauer F, Krug M, Molnár J, Lage H.

Med Chem. 2013 Jun 1;9(4):487-93.

PMID:
23167942
20.

Multitargeted drug development: Discovery and profiling of dihydroxy substituted 1-aza-9-oxafluorenes as lead compounds targeting Alzheimer disease relevant kinases.

Tell V, Holzer M, Herrmann L, Mahmoud KA, Schächtele C, Totzke F, Hilgeroth A.

Bioorg Med Chem Lett. 2012 Nov 15;22(22):6914-8. doi: 10.1016/j.bmcl.2012.09.006. Epub 2012 Sep 13.

PMID:
23039927

Supplemental Content

Loading ...
Support Center